

Triple-negative breast cancer: is there a treatment on th

Oncotarget

8, 1913-1924

DOI: [10.18632/oncotarget.12284](https://doi.org/10.18632/oncotarget.12284)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 835-847.	2.8	52
2	Identification of Breast Cancer Inhibitors Specific for G-protein-Coupled Estrogen Receptor (GPER)-Expressing Cells. <i>ChemMedChem</i> , 2017, 12, 1279-1285.	1.6	47
3	Clinical outcome of brain metastases differs significantly among breast cancer subtypes. <i>Oncology Letters</i> , 2017, 14, 194-200.	0.8	25
4	Small-molecule RL71-triggered excessive autophagic cell death as a potential therapeutic strategy in triple-negative breast cancer. <i>Cell Death and Disease</i> , 2017, 8, e3049-e3049.	2.7	25
5	The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges. <i>Disease Markers</i> , 2017, 2017, 1-14.	0.6	18
6	P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients. <i>PLoS ONE</i> , 2017, 12, e0172324.	1.1	60
7	PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients. <i>International Journal of Oncology</i> , 2018, 52, 755-767.	1.4	15
8	YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 687-695.	1.1	18
9	Cerasomal Lovastatin Nanohybrids for Efficient Inhibition of Triple-Negative Breast Cancer Stem Cells To Improve Therapeutic Efficacy. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 7022-7030.	4.0	23
10	MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1. <i>Cell Death and Disease</i> , 2018, 9, 14.	2.7	124
11	Isoharringtonine inhibits breast cancer stem-like properties and STAT3 signaling. <i>Biomedicine and Pharmacotherapy</i> , 2018, 103, 435-442.	2.5	12
12	Expression and prognostic significance of ECT2 in invasive breast cancer. <i>Journal of Clinical Pathology</i> , 2018, 71, 442-445.	1.0	48
13	Tumor-associated macrophages correlate with phenomenon of epithelial-mesenchymal transition and contribute to poor prognosis in triple-negative breast cancer patients. <i>Journal of Surgical Research</i> , 2018, 222, 93-101.	0.8	87
14	Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells. <i>Journal of Immunotherapy</i> , 2018, 41, 64-72.	1.2	29
15	Autophagy as a Potential Therapeutic Target in Breast Cancer Treatment. <i>Current Cancer Drug Targets</i> , 2018, 18, 629-639.	0.8	10
16	LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers. <i>Oncotarget</i> , 2018, 9, 22586-22604.	0.8	21
17	Actionable Gene Alterations in an Asian Population With Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.	1.5	3
18	Implications of nestin in breast cancer pathogenesis (Review). <i>International Journal of Oncology</i> , 2018, 53, 477-487.	1.4	6

#	ARTICLE	IF	CITATIONS
19	Knockdown of nucleophosmin 1 suppresses proliferation of triple-negative breast cancer cells through activating CDH1/Skp2/p27kip1 pathway. <i>Cancer Management and Research</i> , 2019, Volume 11, 143-156.	0.9	19
20	RASEF expression correlates with hormone receptor status in breast cancer. <i>Oncology Letters</i> , 2018, 16, 7223-7230.	0.8	3
21	Eribulin Treatment Induces High Expression of miR-195 and Inactivates the Wnt/ β -catenin Signaling Pathway in Triple-negative Breast Cancer. <i>The Showa University Journal of Medical Sciences</i> , 2018, 30, 359-370.	0.1	0
22	The Yin and Yang of Natural Compounds in Anticancer Therapy of Triple-Negative Breast Cancers. <i>Cancers</i> , 2018, 10, 346.	1.7	75
23	Nucleolar stress: is there a reverse version?. <i>Journal of Cancer</i> , 2018, 9, 3723-3727.	1.2	11
24	Antitumor activity of NAX060: A novel semisynthetic berberine derivative in breast cancer cells. <i>BioFactors</i> , 2018, 44, 443-452.	2.6	13
25	SOX2 Promotes Cell Proliferation and Metastasis in Triple Negative Breast Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 942.	1.6	59
26	Somatic EP300-G211S mutations are associated with overall somatic mutational patterns and breast cancer specific survival in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 339-351.	1.1	11
27	Integration of Ca ²⁺ signaling regulates the breast tumor cell response to simvastatin and doxorubicin. <i>Oncogene</i> , 2018, 37, 4979-4993.	2.6	29
28	Ciprofloxacin triggers the apoptosis of human triple-negative breast cancer MDA-MB-231 cells via the p53/Bax/Bcl-2 signaling pathway. <i>International Journal of Oncology</i> , 2018, 52, 1727-1737.	1.4	45
29	Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing <i>p15</i> , <i>INK4B</i> , <i>p16</i> , <i>INK4A</i> , and <i>p57</i> transcription. <i>Acta Biochimica Et Biophysica Sinica</i> , 2018, 50, 897-904.	0.9	21
30	β -amino alcohols and their respective 2-phenyl-N-alkyl aziridines as potential DNA minor groove binders. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 657-664.	2.6	16
31	<i>Annona muricata</i> Leaf Extract Triggered Intrinsic Apoptotic Pathway to Attenuate Cancerous Features of Triple Negative Breast Cancer MDA-MB-231 Cells. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-10.	0.5	25
32	(α)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer. <i>Molecules</i> , 2018, 23, 1160.	1.7	37
33	B7-H4 overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancer. <i>Cancer Cell International</i> , 2018, 18, 100.	1.8	28
34	Cellular and Animal Model Studies on the Growth Inhibitory Effects of Polyamine Analogues on Breast Cancer. <i>Medical Sciences (Basel, Switzerland)</i> , 2018, 6, 24.	1.3	12
35	Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study. <i>Clinical Drug Investigation</i> , 2018, 38, 639-648.	1.1	20
36	To Evaluate the Incidence of ER, PR and Her2/Neu Status in Newly Diagnosed Breast Cancer Patients at a Tertiary Care Centre. <i>Indian Journal of Gynecologic Oncology</i> , 2018, 16, 1.	0.1	0

#	ARTICLE	IF	CITATIONS
37	nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. <i>Annals of Oncology</i> , 2018, 29, 1763-1770.	0.6	94
38	A novel 1,4-naphthoquinone-derived compound induces apoptotic cell death in breast cancer cells. <i>Turkish Journal of Biology</i> , 2019, 43, 256-263.	2.1	10
39	Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles. <i>Scientific Reports</i> , 2019, 9, 11632.	1.6	20
40	The Anticancer and Antioxidant Effects of Muscadine Grape Extracts on Racially Different Triple-negative Breast Cancer Cells. <i>Anticancer Research</i> , 2019, 39, 4043-4053.	0.5	27
41	Inhibition of DNA Repair Mechanisms and Induction of Apoptosis in Triple Negative Breast Cancer Cells Expressing the Human Herpesvirus 6 U94. <i>Cancers</i> , 2019, 11, 1006.	1.7	13
42	EGFR-targeted immunoliposomes as a selective delivery system of simvastatin, with potential use in treatment of triple-negative breast cancers. <i>International Journal of Pharmaceutics</i> , 2019, 569, 118605.	2.6	28
43	Recent advances in nanotheranostics for triple negative breast cancer treatment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 430.	3.5	121
44	Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 1068.	1.3	43
45	Promyelocytic Leukemia (PML) gene regulation: implication towards curbing oncogenesis. <i>Cell Death and Disease</i> , 2019, 10, 656.	2.7	12
46	Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion. <i>Frontiers in Oncology</i> , 2019, 9, 1074.	1.3	15
47	Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells. <i>Cancers</i> , 2019, 11, 105.	1.7	26
48	RLIP inhibition suppresses breast-to-lung metastasis. <i>Cancer Letters</i> , 2019, 447, 24-32.	3.2	16
49	Antiproliferative activity and p53 upregulation effects of chalcones on human breast cancer cells. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2019, 34, 1093-1099.	2.5	32
50	Elevated levels of eEF1A2 protein expression in triple negative breast cancer relate with poor prognosis. <i>PLoS ONE</i> , 2019, 14, e0218030.	1.1	15
51	Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain. <i>Drugs</i> , 2019, 79, 969-995.	4.9	49
52	ROS-mediated activation and mitochondrial translocation of CaMKII contributes to Drp1-dependent mitochondrial fission and apoptosis in triple-negative breast cancer cells by isorhamnetin and chloroquine. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 225.	3.5	83
53	An efficient or methodical review of immunotherapy against breast cancer. <i>Journal of Biochemical and Molecular Toxicology</i> , 2019, 33, e22339.	1.4	14
54	Hibiscus flower extract selectively induces apoptosis in breast cancer cells and positively interacts with common chemotherapeutics. <i>BMC Complementary and Alternative Medicine</i> , 2019, 19, 98.	3.7	44

#	ARTICLE	IF	CITATIONS
55	Treatment patterns, health care resource use and outcomes in metastatic triple-negative breast cancer in Germany: retrospective chart review study (OBTAIN). <i>Current Medical Research and Opinion</i> , 2019, 35, 1405-1414.	0.9	9
56	The Novel Mnk1/2 Degrader and Apoptosis Inducer VNLG-152 Potently Inhibits TNBC Tumor Growth and Metastasis. <i>Cancers</i> , 2019, 11, 299.	1.7	18
57	Induction of AMPK activation by N,Nâ€™-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers. <i>PLoS ONE</i> , 2019, 14, e0209392.	1.1	16
58	Different mechanisms involved in the berberineâ€™induced antiproliferation effects in tripleâ€™negative breast cancer cell lines. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 13531-13544.	1.2	33
59	Metabolic Profiling of Amino Acids by Liquid Chromatographyâ€™Tandem Mass Spectrometry (LCâ€™MS) to Characterize the Significance of Glutamine in Triple-Negative Breast Cancer (TNBC). <i>Analytical Letters</i> , 2019, 52, 1068-1082.	1.0	1
60	Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France. <i>BMC Cancer</i> , 2019, 19, 140.	1.1	7
61	The Design and Synthesis of Novel Phenothiazine Derivatives as Potential Cytotoxic Agents. <i>Letters in Drug Design and Discovery</i> , 2019, 17, 57-67.	0.4	4
62	Can we cure stage IV triple-negative breast carcinoma?. <i>Medicine (United States)</i> , 2019, 98, e17251.	0.4	5
63	LRP8 is overexpressed in estrogenâ€™negative breast cancers and a potential target for these tumors. <i>Cancer Medicine</i> , 2019, 8, 325-336.	1.3	18
64	Interplay between Epigenetics, Expression of Estrogen Receptor- β , HER2/ERBB2 and Sensitivity of Triple Negative Breast Cancer Cells to Hormonal Therapy. <i>Cancers</i> , 2019, 11, 13.	1.7	22
65	Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression. <i>Biochemical Pharmacology</i> , 2019, 159, 52-63.	2.0	52
66	FAK is Required for Tumor Metastasis-Related Fluid Microenvironment in Triple-Negative Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 38.	1.0	25
67	Engineered Histidine-Enriched Facial Lipopeptides for Enhanced Intracellular Delivery of Functional siRNA to Triple Negative Breast Cancer Cells. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 4719-4736.	4.0	20
68	Nanosoldiers: A promising strategy to combat triple negative breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2019, 110, 319-341.	2.5	60
69	Pyroptosis: A new frontier in cancer. <i>Biomedicine and Pharmacotherapy</i> , 2020, 121, 109595.	2.5	574
70	Exosomes in triple negative breast cancer: Garbage disposals or Trojan horses?. <i>Cancer Letters</i> , 2020, 473, 90-97.	3.2	43
71	Quantitative proteomics discloses monacolin K-induced alterations in triple-negative breast cancer cell proteomes and phosphoproteomes. <i>Molecular Omics</i> , 2020, 16, 19-30.	1.4	2
72	Arylamide as Potential Selective Inhibitor for Matrix Metalloproteinase 9 (MMP9): Design, Synthesis, Biological Evaluation, and Molecular Modeling. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 349-359.	2.5	15

#	ARTICLE	IF	CITATIONS
73	Subtype specific targeting of calcium signaling in breast cancer. <i>Cell Calcium</i> , 2020, 85, 102109.	1.1	33
74	Nanoengineered Disruption of Heat Shock Protein 90 Targets Drug-Induced Resistance and Relieves Natural Killer Cell Suppression in Breast Cancer. <i>Cancer Research</i> , 2020, 80, 5355-5366.	0.4	9
75	Targeting IL-3R α on tumor-derived endothelial cells blunts metastatic spread of triple-negative breast cancer via extracellular vesicle reprogramming. <i>Oncogenesis</i> , 2020, 9, 90.	2.1	30
76	Epigenetic Regulation and Dietary Control of Triple Negative Breast Cancer. <i>Frontiers in Nutrition</i> , 2020, 7, 159.	1.6	7
78	Effects of doxorubicin associated with amniotic membrane stem cells in the treatment of canine inflammatory breast carcinoma (IPC-366) cells. <i>BMC Veterinary Research</i> , 2020, 16, 353.	0.7	2
79	Statins: HMG-CoA Reductase Inhibitors as Potential Anticancer Agents against Malignant Neoplasms in Women. <i>Pharmaceuticals</i> , 2020, 13, 422.	1.7	14
80	Evaluation of chemotherapy and P2Et extract combination in ex-vivo derived tumor mammospheres from breast cancer patients. <i>Scientific Reports</i> , 2020, 10, 19639.	1.6	11
81	Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 14609-14625.	2.9	30
82	Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4. <i>Frontiers in Oncology</i> , 2020, 10, 1206.	1.3	21
83	Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 286.	1.8	13
84	Current trends and opportunities in targeting p21 activated kinase-1(PAK1) for therapeutic management of breast cancers. <i>Gene</i> , 2020, 760, 144991.	1.0	13
85	Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms?. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106125.	1.1	7
86	Maslinic acid differentially exploits the MAPK pathway in estrogen-positive and triple-negative breast cancer to induce mitochondrion-mediated, caspase-independent apoptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2020, 25, 817-834.	2.2	16
87	Analysis of single-cell transcriptomes links enrichment of olfactory receptors with cancer cell differentiation status and prognosis. <i>Communications Biology</i> , 2020, 3, 506.	2.0	18
88	Pincerâ€Based Heterobimetallic Pt(II)/Ru(II), Pt(II)/Ir(III), and Pt(II)/Cu(I) Complexes: Synthesis and Evaluation of Antiproliferative Properties. <i>European Journal of Inorganic Chemistry</i> , 2020, 2020, 3370-3377.	1.0	10
89	Anti-Metastasis Fascin Inhibitors Decrease the Growth of Specific Subtypes of Cancers. <i>Cancers</i> , 2020, 12, 2287.	1.7	16
90	Can MRI Biomarkers Predict Triple-Negative Breast Cancer?. <i>Diagnostics</i> , 2020, 10, 1090.	1.3	22
91	Anti-metastatic action of an N4-aryl substituted thiosemicarbazone on advanced triple negative breast cancer.. <i>Heliyon</i> , 2020, 6, e05161.	1.4	0

#	ARTICLE	IF	CITATIONS
92	The effect of low frequency and low intensity ultrasound combined with microbubbles on the sonoporation efficiency of MDA-MB-231 cells. <i>Annals of Translational Medicine</i> , 2020, 8, 298-298.	0.7	8
93	Hydrogen sulfide and its donors: Novel antitumor and antimetastatic therapies for triple-negative breast cancer. <i>Redox Biology</i> , 2020, 34, 101564.	3.9	52
94	Extracellular vesicles produced by NFAT3-expressing cells hinder tumor growth and metastatic dissemination. <i>Scientific Reports</i> , 2020, 10, 8964.	1.6	9
95	Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer. <i>Molecular Carcinogenesis</i> , 2020, 59, 1041-1051.	1.3	37
96	Targeted Heating of Mitochondria Greatly Augments Nanoparticle-Mediated Cancer Chemotherapy. <i>Advanced Healthcare Materials</i> , 2020, 9, e2000181.	3.9	19
97	High triple-negative breast cancer prevalence and aggressive prognostic factors in Barbadian women with breast cancer. <i>Cancer</i> , 2020, 126, 2217-2224.	2.0	11
98	Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy. <i>Journal of Biological Chemistry</i> , 2020, 295, 6263-6277.	1.6	38
99	Moderate Exercise Modulates Tumor Metabolism of Triple-Negative Breast Cancer. <i>Cells</i> , 2020, 9, 628.	1.8	13
100	A Bis-Chelating / Ligand for the Synthesis of Heterobimetallic Platinum(II)/Rhenium(I) Complexes: Tools for the Optimization of a New Class of Platinum(II) Anticancer Agents. <i>Chemistry - A European Journal</i> , 2020, 26, 12846-12861.	1.7	14
101	Connexin 43 Modulates the Cellular Resistance to Paclitaxel via Targeting β -Tubulin in Triple-Negative Breast Cancer. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5323-5335.	1.0	6
102	Bifunctional Aptamer-Doxorubicin Conjugate Crosses the Blood-Brain Barrier and Selectively Delivers Its Payload to EpCAM-Positive Tumor Cells. <i>Nucleic Acid Therapeutics</i> , 2020, 30, 117-128.	2.0	41
103	Development of CAPER peptides for the treatment of triple negative breast cancer. <i>Cell Cycle</i> , 2020, 19, 432-447.	1.3	14
104	Reduction of nuclear Y654-catenin expression through SH3GL2-mediated downregulation of EGFR in chemotolerance TNBC: Clinical and prognostic importance. <i>Journal of Cellular Physiology</i> , 2020, 235, 8114-8128.	2.0	7
105	Krebs Cycle Intermediate-Modified Carbonate Apatite Nanoparticles Drastically Reduce Mouse Tumor Burden and Toxicity by Restricting Broad Tissue Distribution of Anticancer Drugs. <i>Cancers</i> , 2020, 12, 161.	1.7	6
106	Knockdown of A-kinase anchor protein 4 inhibits proliferation of triple-negative breast cancer cells in vitro and in vivo. <i>Tumor Biology</i> , 2020, 42, 101042832091447.	0.8	5
107	LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 31-41.	1.1	13
108	Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2078.	1.2	163
109	Hexane Extract of <i>Garcinia quaesita</i> Fruits Induces Apoptosis in Breast Cancer Stem Cells Isolated from Triple Negative Breast Cancer Cell Line MDA-MB-231. <i>Nutrition and Cancer</i> , 2021, 73, 845-855.	0.9	9

#	ARTICLE	IF	CITATIONS
110	Exosome vesicle as a nano-therapeutic carrier for breast cancer. <i>Journal of Drug Targeting</i> , 2021, 29, 121-130.	2.1	12
111	Vitamin D analogues exhibit antineoplastic activity in breast cancer patient-derived xenograft cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 208, 105735.	1.2	9
112	Cold atmospheric plasma modification of curcumin loaded in triphosphate chitosan nanoparticles enhanced breast cancer cells apoptosis. <i>Polymers for Advanced Technologies</i> , 2021, 32, 31-40.	1.6	8
113	Epigenetic Modulation of SPCA2 Reverses Epithelial to Mesenchymal Transition in Breast Cancer Cells. <i>Cancers</i> , 2021, 13, 259.	1.7	8
114	CRISPR/Cas9 based genome editing for targeted transcriptional control in triple-negative breast cancer. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 2384-2397.	1.9	22
115	Role of inflammatory microenvironment: potential implications for improved breast cancer nano-targeted therapy. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 2105-2129.	2.4	13
116	The Added Value of SOX10 Immunohistochemistry to Other Breast Markers in Identifying Cytokeratin 5-Positive Triple Negative Breast Cancers as of Mammary Origin. <i>Pathobiology</i> , 2021, 88, 228-233.	1.9	9
117	Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells. <i>Frontiers in Chemistry</i> , 2020, 8, 602845.	1.8	8
118	Fluorouracil uptake in triple-negative breast cancer cells: Negligible contribution of equilibrative nucleoside transporters 1 and 2. <i>Biopharmaceutics and Drug Disposition</i> , 2021, 42, 85-93.	1.1	3
119	Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2056.	1.8	10
120	USP19 modulates cancer cell migration and invasion and acts as a novel prognostic marker in patients with early breast cancer. <i>Oncogenesis</i> , 2021, 10, 28.	2.1	13
121	Differential reprogramming of breast cancer subtypes in 3D cultures and implications for sensitivity to targeted therapy. <i>Scientific Reports</i> , 2021, 11, 7259.	1.6	20
122	Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2021, 1865, 129841.	1.1	24
123	Epoxyazadiradione induced apoptosis/anoikis in triple-negative breast cancer cells, MDA-MB-231, by modulating diverse cellular effects. <i>Journal of Biochemical and Molecular Toxicology</i> , 2021, 35, 1-17.	1.4	11
124	New Insight into Triple-Negative Breast Cancer Therapy: The Potential Roles of Endoplasmic Reticulum Stress and Autophagy Mechanisms. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, 679-691.	0.9	3
125	An <i>in vitro</i> study on the reversal of epithelial to mesenchymal transition by brusatol and its synergistic properties in triple-negative breast cancer cells. <i>Journal of Pharmacy and Pharmacology</i> , 2021, 73, 749-757.	1.2	13
126	HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models. <i>Cancers</i> , 2021, 13, 2007.	1.7	11
127	Identification of potential metabolic biomarkers of rectal cancer and of the effect of neoadjuvant radiochemotherapy. <i>PLoS ONE</i> , 2021, 16, e0250453.	1.1	12

#	ARTICLE	IF	CITATIONS
128	Role of AMPK and Akt in triple negative breast cancer lung colonization. <i>Neoplasia</i> , 2021, 23, 429-438.	2.3	5
129	Debio-0932, a second generation oral Hsp90 inhibitor, induces apoptosis in MCF-7 and MDA-MB-231 cell lines. <i>Molecular Biology Reports</i> , 2021, 48, 3439-3449.	1.0	12
130	Cholesterol-Induced Metabolic Reprogramming in Breast Cancer Cells Is Mediated via the ERR α Pathway. <i>Cancers</i> , 2021, 13, 2605.	1.7	13
131	Nanodiamonds and their potential applications in breast cancer therapy: a narrative review. <i>Drug Delivery and Translational Research</i> , 2022, 12, 1017-1028.	3.0	7
132	Lovastatin Inhibits EMT and Metastasis of Triple-Negative Breast Cancer Stem Cells Through Dysregulation of Cytoskeleton-Associated Proteins. <i>Frontiers in Oncology</i> , 2021, 11, 656687.	1.3	18
133	Real-World Clinical Outcomes in Biological Subgroups of Breast Cancer in the Hospital District of Southwest Finland. <i>Oncologist</i> , 2021, 26, e1372-e1380.	1.9	6
134	Cytoprotective Effect of Vitamin D on Doxorubicin-Induced Cardiac Toxicity in Triple Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7439.	1.8	11
135	DIF-1 inhibits growth and metastasis of triple-negative breast cancer through AMPK-mediated inhibition of the mTORC1-S6K signaling pathway. <i>Oncogene</i> , 2021, 40, 5579-5589.	2.6	18
136	A new immunochemical strategy for triple-negative breast cancer therapy. <i>Scientific Reports</i> , 2021, 11, 14875.	1.6	6
137	Systems Pharmacology-Based Precision Therapy and Drug Combination Discovery for Breast Cancer. <i>Cancers</i> , 2021, 13, 3586.	1.7	4
138	Prevalence and Mortality of Triple-Negative Breast Cancer in West Africa: Biologic and Sociocultural Factors. <i>JCO Global Oncology</i> , 2021, 7, 1129-1140.	0.8	11
139	Association of statin use with clinical outcomes in patients with triple-negative breast cancer. <i>Cancer</i> , 2021, 127, 4142-4150.	2.0	22
140	Triple-negative breast cancer: understanding Wnt signaling in drug resistance. <i>Cancer Cell International</i> , 2021, 21, 419.	1.8	40
141	[(C ¹³ Au(N ¹⁵)] ⁺ Complexes as a New Family of Anticancer Candidates: Synthesis, Characterization and Exploration of the Antiproliferative Properties. <i>Chemistry - A European Journal</i> , 2021, 27, 15773-15785.	1.7	11
142	New functionalized 6-thienylpyrimidine-5-carbonitriles as antiproliferative agents against human breast cancer cells. <i>Archiv Der Pharmazie</i> , 2021, 354, e2100177.	2.1	5
143	Production and Evaluation of In-vitro and In-vivo Effects of P28-IL24, a Promising Anti-breast Cancer Fusion Protein. <i>International Journal of Peptide Research and Therapeutics</i> , 2021, 27, 2583-2594.	0.9	1
144	Hormone-Dependent Tumors and Sexuality in the Neuro-Oncology of Women (N.O.W.): Women's Brain Tumors, Gaps in Sexuality Considerations, and a Need for Evidence-Based Guidelines. <i>Current Oncology Reports</i> , 2021, 23, 127.	1.8	3
145	Curcumin-cinnamaldehyde hybrids as antiproliferative agents against women's cancer cells. <i>Medicinal Chemistry Research</i> , 0, , 1.	1.1	0

#	ARTICLE	IF	CITATIONS
146	Iron oxide nanoparticle targeted chemo-immunotherapy for triple negative breast cancer. <i>Materials Today</i> , 2021, 50, 149-169.	8.3	33
148	Molecular Classification Models for Triple Negative Breast Cancer Subtype Using Machine Learning. <i>Journal of Personalized Medicine</i> , 2021, 11, 881.	1.1	5
149	The Role of Non-Coding RNAs in Breast Cancer Drug Resistance. <i>Frontiers in Oncology</i> , 2021, 11, 702082.	1.3	11
150	Breast cancer stem cells: A review of their characteristics and the agents that affect them. <i>Molecular Carcinogenesis</i> , 2021, 60, 73-100.	1.3	28
151	Synthesis of micellar-like terpolymer nanoparticles with reductively-cleavable cross-links and evaluation of efficacy in 2D and 3D models of triple negative breast cancer. <i>Journal of Controlled Release</i> , 2020, 323, 549-564.	4.8	13
153	The triacylglycerol, hydroxytrirolein, inhibits triple negative mammary breast cancer cell proliferation through a mechanism dependent on dihydroceramide and Akt. <i>Oncotarget</i> , 2019, 10, 2486-2507.	0.8	15
154	Long non-coding RNAs regulation of therapeutic resistance. , 2019, 2, 550-567.		1
155	Targeted Drug Therapy to Overcome Chemoresistance in Triple-negative Breast Cancer. <i>Current Cancer Drug Targets</i> , 2020, 20, 559-572.	0.8	14
156	Topoisomerase II β Gene alteration in Triple Negative Breast Cancer and Its Predictive Role for Anthracycline-Based Chemotherapy (Egyptian NCI Patients). <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 3581-3589.	0.5	8
157	Apoptotic Resistance of Metastatic Tumor Cells in Triple Negative Breast Cancer: Roles of Death Receptor-5. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 1743-1748.	0.5	10
158	IL-6 Impairs the Activity of Vitamin D3 in the Regulation of Epithelial-Mesenchymal Transition in Triple Negative Breast Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 2267-2273.	0.5	2
159	Synergistic Induction of Apoptosis by the Combination of an Axl Inhibitor and Auranofin in Human Breast Cancer Cells. <i>Biomolecules and Therapeutics</i> , 2020, 28, 473-481.	1.1	12
160	Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1096-1104.	2.3	33
161	Crystallization of the Multi-Receptor Tyrosine Kinase Inhibitor Sorafenib for Controlled Long-Term Drug Delivery Following a Single Injection. <i>Cellular and Molecular Bioengineering</i> , 2021, 14, 471-486.	1.0	0
164	Androgen Receptor Expression and Its Correlation with Clinicopathological Parameters in Iranian Patients with Triple Negative Breast Cancer. <i>Iranian Journal of Pathology</i> , 2020, 15, 239-244.	0.2	2
166	Synthesis and Antiproliferative Evaluation of 3-Chloroazetid-2-ones with Antimitotic Activity: Heterocyclic Bridged Analogues of Combretastatin A-4. <i>Pharmaceuticals</i> , 2021, 14, 1119.	1.7	7
167	Chick Embryo Experimental Platform for Micrometastases Research in a 3D Tissue Engineering Model: Cancer Biology, Drug Development, and Nanotechnology Applications. <i>Biomedicines</i> , 2021, 9, 1578.	1.4	2
168	An Insight into the Role of Bee Venom and Melittin Against Tumor Cells: A Review of Breast Cancer therapy. <i>Archives of Breast Cancer</i> , 0, , 267-276.	0.0	1

#	ARTICLE	IF	CITATIONS
169	Cancer-associated fibroblast-derived LRRC15 promotes the migration and invasion of triple-negative breast cancer cells via Wnt/ β -catenin signalling pathway regulation. <i>Molecular Medicine Reports</i> , 2021, 25, .	1.1	11
170	The Cytotoxicity of RNase-Derived Peptides. <i>Biomolecules</i> , 2021, 11, 16.	1.8	6
171	Pharmacologic Modulation of the Immune Response Against Tumours in the Elderly. , 2020, , 157-164.		0
173	Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence. <i>Expert Review of Vaccines</i> , 2022, 21, 337-353.	2.0	9
174	Treatment Strategies Against Triple-Negative Breast Cancer: An Updated Review. <i>Breast Cancer: Targets and Therapy</i> , 2022, Volume 14, 15-24.	1.0	15
175	Epigenetic Priming with Decitabine Augments the Therapeutic Effect of Cisplatin on Triple-Negative Breast Cancer Cells through Induction of Proapoptotic Factor NOXA. <i>Cancers</i> , 2022, 14, 248.	1.7	3
176	Construction and Validation of a Prognostic Risk Model for Triple-Negative Breast Cancer Based on Autophagy-Related Genes. <i>Frontiers in Oncology</i> , 2022, 12, 829045.	1.3	11
177	CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 989.	1.7	8
178	Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6. <i>Npj Breast Cancer</i> , 2022, 8, 30.	2.3	14
179	Combination of Second-Generation Proteasome Inhibitor Carfilzomib with Bortezomib in Four Different Breast Cancer Cell Lines. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 2909-2918.	0.9	0
180	Nm23-H1 activator phenylbutenoid dimer exerts cytotoxic effects on metastatic breast cancer cells by inducing mitochondrial dysfunction only under glucose starvation. <i>Scientific Reports</i> , 2021, 11, 23549.	1.6	3
181	Current Photoactive Molecules for Targeted Therapy of Triple-Negative Breast Cancer. <i>Molecules</i> , 2021, 26, 7654.	1.7	11
196	Alpha-mangostin as an inhibitor of GSK3 β in triple-negative breast cancer. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 4515-4521.	2.0	2
197	Receptor-Targeted Surface-Engineered Nanomaterials for Breast Cancer Imaging and Theranostic Applications. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2022, 39, 1-44.	1.2	14
198	Different drug delivery approaches in combinational therapy in TNBC. , 2022, , 201-230.		6
199	Treatment Response Monitoring Using a Tumor-Informed Circulating Tumor DNA Test in an Advanced Triple-Negative Breast Cancer Patient: A Case Report. <i>Case Reports in Oncology</i> , 2022, 15, 473-479.	0.3	7
200	Three-Dimensional Organotypic Cultures Reshape the microRNAs Transcriptional Program in Breast Cancer Cells. <i>Cancers</i> , 2022, 14, 2490.	1.7	6
201	Thymoquinone Alterations of the Apoptotic Gene Expressions and Cell Cycle Arrest in Genetically Distinct Triple-Negative Breast Cancer Cells. <i>Nutrients</i> , 2022, 14, 2120.	1.7	6

#	ARTICLE	IF	CITATIONS
202	Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	0
203	The combined restoration of miR-424-5p and miR-142-3p effectively inhibits MCF-7 breast cancer cell line via modulating apoptosis, proliferation, colony formation, cell cycle and autophagy. <i>Molecular Biology Reports</i> , 2022, 49, 8325-8335.	1.0	8
204	Cytotoxic and antiparasitic activities of diphosphine-metal complexes of group 10 containing acylthiourea as ligands. <i>Journal of Inorganic Biochemistry</i> , 2022, 234, 111906.	1.5	4
205	Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
206	Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment. <i>Pharmaceuticals</i> , 2022, 15, 881.	1.7	10
207	Vitamin D: an essential adjuvant therapeutic agent in breast cancer. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211138.	0.4	3
209	Interleukin-3-Receptor- α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target. <i>Cancers</i> , 2022, 14, 3918.	1.7	6
210	Evaluation of anticancer effects of frankincense on breast cancer stem-like cells. <i>Cancer Reports</i> , 0, , .	0.6	3
211	Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1 α /miR-494/Survivin signaling pathway. <i>Neoplasia</i> , 2022, 32, 100821.	2.3	16
212	Oncogenic and Stemness Signatures of the High-Risk HCMV Strains in Breast Cancer Progression. <i>Cancers</i> , 2022, 14, 4271.	1.7	10
213	The Effect of Neoadjuvant vs Adjuvant Chemotherapy on Final Outcome of Patients with Triple Negative Breast Cancer. <i>Medical Journal of the Islamic Republic of Iran</i> , 0, , .	0.9	1
214	Simvastatine. <i>Medecine/Sciences</i> , 2022, 38, 646-647.	0.0	0
215	Ligand-Specific Nano-Contrast Agents Promote Enhanced Breast Cancer CT Detection at 0.5 mg Au. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9926.	1.8	2
216	Hypoxia Triggers TAZ Phosphorylation in Basal A Triple Negative Breast Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10119.	1.8	2
217	Chemotherapeutic Protocols for the Treatment of Breast Cancer. , 2022, , 79-123.		0
219	Synthesis and Structure-Activity Relationship Studies of Novel Aryl Sulfonamides and Their Activity against Human Breast Cancer Cell Lines. <i>Chemistry and Biodiversity</i> , 2022, 19, .	1.0	0
220	Targeting Triple Negative Breast Cancer Stem Cells by Heat Shock Protein 70 Inhibitors. <i>Cancers</i> , 2022, 14, 4898.	1.7	5
221	Unique therapeutic potentialities of exosomes based nanodrug carriers to target tumor microenvironment in cancer therapy. <i>OpenNano</i> , 2022, 8, 100091.	1.8	8

#	ARTICLE	IF	CITATIONS
222	The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
223	New tricyclic systems as photosensitizers towards triple negative breast cancer cells. <i>Archives of Pharmacal Research</i> , 2022, 45, 806-821.	2.7	16
224	Therapeutic significance of molecular hybrids for breast cancer research and treatment. <i>RSC Medicinal Chemistry</i> , 0, , .	1.7	3
225	High percentage of Cancer Stem cells in metastatic locations: Upregulation of cicBIRC6 in highly metastatic breast Cancer Subline. <i>Molecular Biology Reports</i> , 2023, 50, 1303-1309.	1.0	2
226	In Vitro Self-Assembly of a Modified Diphenylalanine Peptide to Nanofibers Induced by the Eye Absent Enzyme and Alkaline Phosphatase and Its Activity against Breast Cancer Cell Proliferation. <i>ACS Applied Bio Materials</i> , 2023, 6, 164-170.	2.3	2
227	Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers. <i>Cancers</i> , 2023, 15, 403.	1.7	3
229	Benzoxazole-appended piperidine derivatives as novel anticancer candidates against breast cancer. <i>Bioorganic Chemistry</i> , 2023, 134, 106437.	2.0	5
230	Breast cancer-related mortality in Central and Eastern Europe: years of life lost and productivity costs. <i>Journal of Medical Economics</i> , 2023, 26, 254-261.	1.0	4
231	Discovery of aminothiazole derivatives as a chemical scaffold for glutaminase inhibition. <i>Results in Chemistry</i> , 2023, 5, 100842.	0.9	0
232	Radiosensitization of Breast Cancer Cells with a 2-Methoxyestradiol Analogue Affects DNA Damage and Repair Signaling In Vitro. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3592.	1.8	0
233	A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer. <i>Journal of Advanced Research</i> , 2023, 54, 271-292.	4.4	15
234	Critical Review on the Different Roles of Exosomes in TNBC and Exosomal-Mediated Delivery of microRNA/siRNA/lncRNA and Drug Targeting Signalling Pathways in Triple-Negative Breast Cancer. <i>Molecules</i> , 2023, 28, 1802.	1.7	2
235	Proteomic profiling and ROC analysis identify CD151 and ELAVL1 as potential therapy response markers for the antiviral drug in resistant TNBC. <i>Life Sciences</i> , 2023, 320, 121534.	2.0	1
236	S1P1 Threonine 236 Phosphorylation Mediates the Invasiveness of Triple-Negative Breast Cancer and Sensitivity to FTY720. <i>Cells</i> , 2023, 12, 980.	1.8	2
237	Integrated virtual screening and molecular dynamics simulation approaches revealed potential natural inhibitors for DNMT1 as therapeutic solution for triple negative breast cancer. <i>Journal of Biomolecular Structure and Dynamics</i> , 2024, 42, 1099-1109.	2.0	7
238	An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
239	Regulation of ER α -dependent breast cancer metastasis by a miR-29a signaling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	3